Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at the 23
Annual Oppenheimer Healthcare Conference being held December 12-13, 2012 at the Waldorf-Astoria in New York, NY. The presentation details are as follows:
- A panel discussion titled “Toward Personalized Medicine” on Thursday, December 13, 2012 at 8:35 am ET in the Jade room.
- Corporate presentation on Thursday, December 13, 2012 at 1:35 pm ET in the Basildon room.
Webcasts of the presentations can be accessed by visiting the investors section of the Company’s website at
. A replay of the webcasts will be archived on the Verastem website for two weeks following the presentation date.
About Verastem, Inc.
Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.